世界の抗アレルギー薬市場：OTCへのスイッチ

Abstract

Why is the World Allergies Market Important?

The number of people suffering from some sort of allergy is on the rise and the demand for reliable treatments for allergic rhinitis and other allergic conditions is on the rise worldwide. The market is a mature one with a number of high profile patent losses in the near future and a strong OTC segment. Will there be a replacement for Zyrtec or Allegra in the near Future? What role will the new improved vaccines play in the next five years? Read visiongain's new report to find out.

What is contained in the report?

The report covers all aspects of the current allergy market, including

• A brief introduction into the biology of allergies
• A market forecast for the world prescription market 2006-2011
• Geographic breakdowns for sales revenues
• A SWOT analysis of the allergic rhinitis market
• Summaries and forecasts for the leading antihistamines and corticosteroids
• An assessment of the drivers and restraints of the market
• A discussion of the strategy of Rx-OTC switching
• A review of the OTC market for allergic rhinitis
• Analysis of treatments of eczema and allergic conjunctivitis

This report consists of over 100 pages and over 50 tables and figures.

Table of Contents

1. Executive Summary

• 1.1 Aims of the Report
• 1.2 Summary of Contents

2. Introduction

• 2.1 Allergies Defined and Explained
  • 2.1.1 IgEs and Mast Cells Mediate Allergic Reactions
• 2.2 Allergic Rhinitis
  • 2.2.1 Seasonal Allergic Rhinitis (Hay Fever)
  • 2.2.2 Perennial Allergic Rhinitis
• 2.3 Other Allergies
  • 2.3.1 Food Allergies
  • 2.3.2 Other Common Allergens
• 2.4 The Epidemiology of Allergic Rhinitis
  • 2.4.1 Risk Factors
  • 2.4.2 Co-morbidities
• 2.5 The Treatment of Allergic Rhinitis
  • 2.5.1 First Generation Antihistamine Tablets
  • 2.5.2 Second Generation (Non-sedating) Antihistamines
  • 2.5.3 Nasal Corticosteroids
  • 2.5.4 Other Antihistamine Treatments
  • 2.5.5 Nasal Cromoglycate (Cromolyn)
  • 2.5.6 Decongestants
  • 2.5.7 Immunotherapy (Vaccines)
• 2.6 Antihistamines and Corticosteroids are The Main Form of Treatment
• 2.7 OTC Treatments are a Large Part of the Market
  • 2.7.1 Claritin - a Landmark Case
• 2.8 Patent Expiry Will Be High But OTC Growth Will Soften the Blow
• 2.9 Allergic Rhinitis Vaccines May Soon be Effective and Will Take Significant Market Share

3. The World Market for Allergic Rhinitis

• 3.1 The World Prescription Market for Rhinitis Treatment Shows Steady Growth
  • 3.1.1 The 2005 Market for Allergic Rhinitis is Worth over $8bn
  • 3.1.2 Zyrtec is the Leading Allergic Rhinitis Drug
• 3.2 Prescription Drug Market Remains Steady Despite Patent Loss
  • 3.2.1 Patent Loss is Predicted to Continue
  • 3.2.2 Follow-on Antihistamines Hope to Stem Generic Erosion of Revenues
• 3.3 Antihistamines Remain the Principal Rhinitis Treatment
  • 3.3.1 Over Two Thirds of Prescription Revenues are from Antihistamines
  • 3.3.2 Nasal Corticosteroids Show the Highest Growth
• 3.4 The Growth of the OTC Market Will Continue
  • 3.4.1 OTC Switching Reduces the Impact of Generic Competition but Does Not Negate it
  • 3.4.2 More OTC Switches on The Way
• 3.5 Visiongain Predicts Negative Growth for the Total Allergic Rhinitis Market
  • 3.5.1 The Market Will Decline Sharply
  • 3.5.2 Corticosteroids Will Gain Market Share

4. The World Allergic Rhinitis Market by Geographic Region

• 4.1 The US Dominates the Rx Market
  • 4.1.1 There are Regional Variations on the Class of Drugs Preferred
• 4.2 Europe Leads the OTC Market for Allergic Rhinitis
• 4.3 Growth in the Developing Markets Will Remain Low

5. The World Antihistamine Market for Allergic Rhinitis

• 5.1 Summary of the World Antihistamine Market, 2005
  • 5.1.1 The Top Two Drugs Control over 70% of the Market
• 5.2 The Entire Prescription Antihistamine Market is Facing Decline
• 5.3 Zyrtex and Clarinex Face Imminent Patent Loss
  • 5.3.1 Zrytec is Well Positioned for an OTC Switch
  • 5.3.2 Allegra Revenues Will Continue to Suffer from Generic Competition
  • 5.3.3 Clarinex Prepares to Replace Claritin OTC
• 5.4 Other Brands Will Not Support the Market in the Future
  • 5.4.1 Claritin Sales Will Decline as Clarinex Goes Generic
  • 5.4.2 Xyzal
  • 5.4.3 Allelock Will Thrive in the Japanese Market
• 5.5 Other Brands are Growing but Revenues are Relatively Small
• 5.6 Is OTC Switching a Viable Future Strategy for the Ailing Antihistamine Market?

6. The World Steroid Market for Allergic Rhinitis

• 6.1 Summary of the World Corticosteroid Market, 2005
  • 6.1.1 Flonase Dominates the Market
• 6.2 World Steroids Market to Hold Steady Until 2011
  • 6.2.1 Flonase Begins to Feel the Effects of Patent Loss
  • 6.2.2 New Indications and Formulations Drive Nasonex Growth
  • 6.2.3 Rhinocort
  • 6.2.4 Nasacort
• 6.3 Conclusion: The World Market for Nasal Corticosteroids Will Maintain Value Due to Sales of Nasonex

7. The World OTC Market for Allergic Rhinitis

• 7.1 New Switches and New Formulations Drive OTC Revenue Growth
  • 7.1.1 Claritin OTC-switch Had Little Effect on Existing OTC Brands
  • 7.1.2 The European and US OTC Markets are Different
  • 7.1.3 Flonase Switch in the US Will Drive the Market Early in the Forecast Period
• 7.2 OTC Switches are Favoured by Insurers and Health Services
• 7.3 Pharmacist Recommendations are Key in OTC Allergy Products
  • 7.3.1 Decongestants Play a Large Role in OTC Anti-Allergy Treatments
• 7.4 The OTC Market Will Peak in 2008

8. SWOT Analysis of the Allergic Rhinitis Market

• 8.1 Summary of Strengths, Weaknesses, Opportunities and Threats
• 8.2 High Prevalence Drives the Market
• 8.3 Low Rate of Adverse Effects is a Clear Advantage
• 8.4 Anti-allergy Drugs are Obvious Targets for OTC Switching
• 8.5 There are Disadvantages of OTC Dominance
• 8.6 Generic Companies Will Target Allergic Rhinitis Treatments
• 8.7 The OTC Decision is Key for the Allergic Rhinitis Market
  • 8.7.1 US Authorisation for OTC
  • 8.7.2 OTC Status in Other Countries
  • 8.7.3 Considerations for the OTC Decision in the Allergic Rhinitis Market
  • 8.7.4 Timing is Everything in the Anti-Allergy Markets
• 8.8 Unmet Needs: Persistent Sufferers Require Reliable and Convenient Treatments

9. Future Developments

• 9.1 New Takes on Established Treatments Will Help Stem the Tide After Patent Loss
  • 9.1.1 Schering Plough and Merck Invest in Combination Therapy
  • 9.1.2 GSK Attempts to Emulate Nasonex's Success
  • 9.1.3 Is efletirizine Zyrtec's True Successor?
• 9.2 Immunotherapy Aims to Meet Unmet Needs
  • 9.2.1 Grazax
  • 9.2.2 Pollinex-Quattro
  • 9.2.3 Curalogic - Three 'vaccines' at Phase II or above
  • 9.2.4 Cytos' QbG10 Technology May Offer Allergen Independent Relief
• 9.3 Development of New Asthma Treatments Will Lead to a New Allergy Drugs
  • 9.3.1 From Proteins to Oligos - A Variety of Modes of Action
  • 9.3.2 MAbs May Prove Technically Difficult and Expensive

10. Other Allergy Drugs

• 10.1 Allergic Conjunctivitis
• 10.2 Atopic dermatitis
  • 10.2.1 The Market for Topical Eczema Treatments is Small and Shrinking
  • 10.2.2 Non-steroidal Treatments Lead the Prescription Market

11. Conclusion: A Mature Market in Need of Innovation

• 11.1 The Allergy Market is Divided Into Sub-markets
• 11.2 OTC May be the Answer For Some But Not All
• 11.3 The Use of Vaccines is Set to Increase

List of Figures

• Figure 3.1, Total Revenues ($m) for the Top Ten Allergic Rhinitis Treatments, 2004-2005
• Figure 3.2, Growth Rates (%) for the Top Ten Allergic Rhinitis Treatments, 2004-2005
• Figure 3.3, Allergic Rhinitis Market Share by Brand, 2005
• Figure 3.4, Allergic Rhinitis Market Share by Mode of Action, 2005
• Figure 3.5, Growth Rates (%) for Allergic Rhinitis Treatments by Mode of Action, 2004-2005
• Figure 3.6, Total Schering Plough Revenues for Claritin, 2002-2005
• Figure 5.1, Market Share by Drug for Antihistamines, 2005
• Figure 5.2, World Revenues for Prescription Antihistamines, 2004-2011
• Figure 5.3, Revenue Forecast for Zyrtec, 2005-2011
• Figure 5.4, Revenue Forecast for Allegra, 2005-2011
• Figure 5.5, Revenue Forecast for Clarinex, 2005-2011
• Figure 5.6, Revenue Forecast for Claritin, 2005-2011
• Figure 5.7, Revenue Forecast for Xyzal, 2005-2011
• Figure 5.8, Revenue Forecast for Allelock, 2005-2011
• Figure 5.9, Revenue Forecast for Other Branded Antihistamines, 2005-2011
• Figure 6.1, Leading Nasal Corticosteroids by Market Share, 2005
• Figure 6.2, World Revenue Forecast for the Leading Corticosteroids, 2005-2011
• Figure 6.3, Revenue Forecast for Flonase, 2005-2011
• Figure 6.4, Revenue Forecast for Nasonex, 2005-2011
• Figure 6.5, Revenue Forecast for Rhinocort, 2005-2011
• Figure 6.6, Revenue Forecast for Nasacort, 2005-2011
• Figure 7.1, Brands Recommended by Pharmacists, 2005
• Figure 8.1, Branded Drugs Facing Generic Compeition, 2005-2011
• Figure 10.1, Revenues ($m) for Leading Atopic Dermatitis Treatments, 2005
• Figure 10.2, Market Share for Leading Atopic Dermatitis Treatments, 2005

List of Tables

• Table 3.1, Total Revenues and Growth Rates of Leading Allergic Rhinitis Treatments, 2004-2005
• Table 3.2, US Patent Expiry Dates for Selected Allergic Rhinitis Treatments, 2006
• Table 3.3, Antihistamines and Their Follow-Up Products, 2006
• Table 3.4, Total Schering Plough Revenues for Claritin, 2002-2005
• Table 3.5, World Market Forecast for Allergic Rhinitis Treatments, 2004-2011
• Table 4.1, Market Share for Allergic Rhinitis by Country, 2005
• Table 4.2, Allergic Rhinitis Markets in Selected Developing Countries, 2005
• Table 5.1, Leading Prescription Antihistamines, 2005
• Table 5.2, Forecast Revenues for Antihistamines, 2004-2011
• Table 5.3, Revenue Forecast for Zyrtec, 2004-2011
• Table 5.4, Revenue Forecast for Allegra, 2004-2011
• Table 5.5, Revenue Forecast for Clarinex, 2004-2011
• Table 5.6, Revenue Forecast for Claritin, 2004-2011
• Table 5.7, Revenue Forecast for Xyzal, 2004-2011
• Table 5.8, Revenue Forecast for Allelock, 2004-2011
• Table 6.1, Leading Prescription Nasal Corticosteroids, 2005
• Table 6.2, World Revenue Forecast for the Leading Corticosteroids, 2004-2011
• Table 6.3, Combined Q1 and Q2 Revenues For Flonase, 2006
• Table 6.4, Revenue Forecast for Flonase, 2004-2011
• Table 6.5, Revenue Forecast for Nasonex, 2004-2011
• Table 6.6, Revenue Forecast for Rhinocort, 2004-2011
• Table 6.7, Revenue Forecast for Nasacort, 2004-2011
• Table 7.1, Candidates for Rx-OTC Switching
• Table 8.1, Summary of Strengths, Weaknesses, Opportunities and Threats for the Allergic Rhinitis Market
• Table 9.1, Combination Therapies and Follow-on Products in the Pipeline,2006
• Table 9.2, Immunotherapy Products in the Pipeline, 2006
• Table 9.3, Pipeline Drugs Indicated for Asthma and Allergic Rhinitis, 2006
• Table 10.1, Treatments for Allergic Conjunctivitis
• Table 10.2, Leading Treatments for Atopic Dermatitis, 2005
• Table 11.1, Selected Allergy Vaccines in Development

Organisation Listed

• Alcon Inc
• ALK-Abello
• Allergan
• Allergy Therapeutics Plc
• Astellas Pharma
• AstraZeneca
• Barr
• Bausch & Lomb
• Biogen Idec
• Boehringer Ingelheim
• Cambridge Antibody Technologies
• Coley Pharmaceutical Group
• Connetics
• Curalogic
• Cytos
• Daiichi Sankyo
• Dainippon Sumitomo
• Elbion
• Evolutec
• GSK
• H. Lundbeck
• Inflazyme
• Kyowa Hakko Kogyo
• MedPointe Pharmaceuticals.
• Merck and Co.
• Mylan, Impax and Dr Reddy's
• Novartis
• Pfizer
• Prasco Labs
• Rigel Pharmaceuticals
• Sanofi-Aventis
• Santen Pharmaceutical
• Schering-Plough
• Shionogi
• Tanabe Seiyaku
• Teva
• UCB